AnywhereNow Announces the Sale of IQ Messenger to Main Capital Partners GlobeNewswire January 06, 2026 The sale to Main Capital Partners will drive accelerated international growth for IQ Messenger, whilst allowing AnywhereNow to focus on its core Customer Experience SaaS activities. Rotterdam, Netherlands. 6th January, 2026 – Anywhere365 Group B.V. (“AnywhereNow”), a global pioneer and […]

Vancouver, British Columbia–(Newsfile Corp. – January 6, 2026) – Tiger Gold Corp. (TSXV: TIGR) (“Tiger” or the “Company”) is pleased to announce that its common shares have commenced trading today on the Frankfurt Stock Exchange (“FSE”) under the ticker symbol D150, and that the company has entered into a number of market awareness and investor

HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced that the first patient has been dosed in a Phase

CHICAGO and SAN FRANCISCO and SYDNEY, Jan. 06, 2026 (GLOBE NEWSWIRE) — GTreasury, a Ripple Solution, today announced the acquisition of Solvexia, a leading provider of no-code financial automation, data management, and analytics solutions. The acquisition expands GTreasury's platform to automate reconciliation and regulatory reporting across treasury, finance, and compliance operations, addressing one of the

(NasdaqGM:OCS),(Iceland:OCS),(Iceland:OCS.IC), ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) — Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis GlobeNewswire January 06, 2026 ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) — Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies,

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies GlobeNewswire January 06, 2026 HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering

GTreasury Acquires Solvexia to Revolutionize Reconciliation and Regulatory Reporting Acquisition Extends “No Friction, No Boundaries” Vision with Enterprise-Class Automation for Treasury, Finance, and Compliance GlobeNewswire January 06, 2026 CHICAGO and SAN FRANCISCO and SYDNEY, Jan. 06, 2026 (GLOBE NEWSWIRE) — GTreasury, a Ripple Solution, today announced the acquisition of Solvexia, a leading provider of no-code

(Euronext Amsterdam:TOM2),(NasdaqGM:SOUN), LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) — TomTom (TOM2), the specialist in mapping and location technology, and SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and conversational AI, today announced a partnership to showcase a unified in-car AI voice and navigation experience. The collaboration integrates TomTom AI Agent and Automotive

(TSX-V:ROCK),(OTC US:TRDTF),(Other OTC:TRDTF), Vancouver, BC, Jan. 06, 2026 (GLOBE NEWSWIRE) — Trident Resources Corp. (TSX-V: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company“) is pleased to announce the appointment of Mr. Tim Termuende as Chairman of the Board of Directors, effective immediately. Mr. Termuende previously served as a member of the Company's Board. Mr. Termuende is